vosaroxin + decitabine

Vosaroxin + decitabine is an investigational combination therapy studied primarily in older patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Vosaroxin is a first-in-class anticancer quinolone derivative that acts as a DNA intercalator and inhibits topoisomerase II, leading to site-selective DNA double-strand breaks, G2/M cell cycle arrest, and apoptosis. Decitabine is a hypomethylating agent that incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and reactivation of silenced genes. The combination has shown promising efficacy with acceptable tolerability at lower doses of vosaroxin (70 mg/m²), achieving high response rates in phase II studies among older or unfit AML/MDS patients[1][2][4].

Other names

vosaroxin plus decitabineAML18 Arm BAML-18 Arm BAML 18 Arm B